Ryo Maeda1, Junji Yoshida1, Genichiro Ishii2, Tomoyuki Hishida1, Mitsuyo Nishimura1, Kanji Nagai3. 1. Department of Thoracic Oncology, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. 2. Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. 3. Department of Thoracic Oncology, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: knagai@east.ncc.go.jp.
Abstract
OBJECTIVES: The purpose of this study was to evaluate risk factors for tumor recurrence in patients with completely resected early-stage non-small cell lung cancer (NSCLC). METHODS: Between July 1992 and December 2007, 1,967 consecutive patients with stage I and II NSCLC with diagnoses based on the seventh edition TNM classification underwent complete resection. All patients were divided into three groups according to the stage and presence of lymph node metastasis: stage I, patients with stage I, T1-T2aN0M0 disease; stage IIN0, patients with stage II, T2b-T3N0M0, node-negative disease; and stage IIN1, patients with stage II, T1-2N1M0, node-positive disease. Freedom from recurrence rate was estimated using the Kaplan-Meier method, and recurrence risk factors were identified by univariate and multivariate analyses. RESULTS: The 5-year freedom from recurrence rates for stage I, stage IIN0, and stage IIN1 patients were 84%, 61%, and 54%, respectively. By multivariate analyses, three variables (histologic differentiation, vessel invasion, and visceral pleural invasion) in stage I and two variables (adenocarcinoma histology and visceral pleural invasion) in stage IIN0 and stage IIN1 were shown to be independently significant risk factors for recurrence. According to subgroup analyses that combined these risk factors in each group, the 5-year freedom from recurrence rate was 63% for stage I with three risk factors, whereas those for stage IIN0 and stage IIN1 without risk factors were 83% and 78%, respectively. CONCLUSION: In patients with stage I and II NSCLC, we identified risk factors for recurrence. When these factors are combined, high- and low-risk subgroups can be identified within each group.
OBJECTIVES: The purpose of this study was to evaluate risk factors for tumor recurrence in patients with completely resected early-stage non-small cell lung cancer (NSCLC). METHODS: Between July 1992 and December 2007, 1,967 consecutive patients with stage I and II NSCLC with diagnoses based on the seventh edition TNM classification underwent complete resection. All patients were divided into three groups according to the stage and presence of lymph node metastasis: stage I, patients with stage I, T1-T2aN0M0 disease; stage IIN0, patients with stage II, T2b-T3N0M0, node-negative disease; and stage IIN1, patients with stage II, T1-2N1M0, node-positive disease. Freedom from recurrence rate was estimated using the Kaplan-Meier method, and recurrence risk factors were identified by univariate and multivariate analyses. RESULTS: The 5-year freedom from recurrence rates for stage I, stage IIN0, and stage IIN1 patients were 84%, 61%, and 54%, respectively. By multivariate analyses, three variables (histologic differentiation, vessel invasion, and visceral pleural invasion) in stage I and two variables (adenocarcinoma histology and visceral pleural invasion) in stage IIN0 and stage IIN1 were shown to be independently significant risk factors for recurrence. According to subgroup analyses that combined these risk factors in each group, the 5-year freedom from recurrence rate was 63% for stage I with three risk factors, whereas those for stage IIN0 and stage IIN1 without risk factors were 83% and 78%, respectively. CONCLUSION: In patients with stage I and II NSCLC, we identified risk factors for recurrence. When these factors are combined, high- and low-risk subgroups can be identified within each group.
Authors: Linda W Martin; Jonathan D'Cunha; Xiaofei Wang; Debra Herzan; Lin Gu; Naif Abraham; Todd L Demmy; Frank C Detterbeck; Shawn S Groth; David H Harpole; Mark J Krasna; Kemp Kernstine; Leslie J Kohman; G Alexander Patterson; David J Sugarbaker; Robin T Vollmer; Michael A Maddaus; Robert A Kratzke Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: J M Galbis-Caravajal; A Lafuente-Sanchis; M Estors-Guerrero; N Martinez-Hernández; C Fuster-Diana; A Cremades; Á Zúñiga Journal: Clin Transl Oncol Date: 2017-01-27 Impact factor: 3.405
Authors: David D Stenehjem; Brandon K Bellows; Kraig M Yager; Joshua Jones; Rajesh Kaldate; Uwe Siebert; Diana I Brixner Journal: Oncologist Date: 2015-11-27
Authors: J L Lopez Guerra; D R Gomez; S H Lin; L B Levy; Y Zhuang; R Komaki; J Jaen; A A Vaporciyan; S G Swisher; J D Cox; Z Liao; D C Rice Journal: Ann Oncol Date: 2012-09-20 Impact factor: 32.976